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A B S T R A C T
Hematopoietic cell transplantation (HCT) is a rapidly evolving ﬁeld with active preclinical and clinical devel-
opment of new strategies for patient assessment, graft selection and manipulation, and pre- and post-
transplantation drug and cell therapy. New strategies require evaluation in deﬁnitive clinical trials; however,
HCT trials face unique challenges, including the relatively small number of transplantations performed at any
single center, the diverse indications for HCT requiring dissimilar approaches, the complex nature of the in-
tervention itself, the risk of multiple complications in the immediate post-transplantation period, and the risk
of important, though infrequent, late effects. The Blood and Marrow Transplant Clinical Trials Network (BMT
CTN) was established by the US National Heart Lung and Blood Institute and the National Cancer Institute to
meet these challenges. In its 15 years as a network, the BMT CTN has proven to be a successful infrastructure
for planning, implementing, and completing such trials and for providing deﬁnitive answers to questions leading
to improvements in the understanding and practice of HCT. It has opened 37 trials, about one-half phase 2
and one-half phase 3, enrolled more than 8000 patients, and published 57 papers addressing important issues
in the treatment of patients with life-threatening malignant and nonmalignant blood disorders. This review
describes the network’s accomplishments, key components of its success, lessons learned over the past 15
years, and challenges for the future.
© 2016 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
INTRODUCTION
About 21,000 hematopoietic cell transplantations (HCTs)
will be performed in the United States in 2016 and 65,000
will be performed worldwide (Center for International Blood
and Marrow Transplant Research, unpublished data). HCT is
a rapidly evolving ﬁeld with active preclinical and clinical de-
velopment of new approaches to patient assessment, graft
selection andmanipulation, and pre- and post-transplantation
drug and cell therapy. New diagnostic and therapeutic strat-
egies require evaluation in deﬁnitive clinical trials as does the
role of HCT versus other therapies. However, HCT trials face
unique challenges, including the relatively small number of
transplantations performed at any single center, the diverse
indications for HCT requiring dissimilar approaches, the
complex nature of the intervention itself, the risk of multi-
ple complications in the immediate post-transplantation
period, and the risk of important, though infrequent, late
effects. Although there is a longstanding mechanism for in-
vestigators to collaboratively conduct observational HCT
studies in the United States using data collected by the Center
for International Blood and Marrow Transplant Research
(CIBMTR), the ability to collaboratively develop and imple-
mentmulticenter interventional HCT trials was long hampered
by limited funding, by the low priority afforded to HCT trials
both by networks focused on non-HCT cancer therapy and
by pharmaceutical companies, and by lack of an effectivemul-
ticenter HCT trials infrastructure [1,2].
To address this need, in 2001, the National Institute of
Health’s (NIH) National Heart, Lung, and Blood Institute
(NHLBI) and National Cancer Institute (NCI) issued a Request
for Applications (RFA) (HLA-01-004), inviting participation
in a Blood and Marrow Transplant Clinical Trials Network
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(BMT CTN). The objective of the RFA was to establish and
maintain the necessary infrastructure to conduct large, multi-
institutional clinical trials to improve HCT outcomes. The
mandate was to execute large phase 2 and 3 trials with broad
national participation. In its 15 years as a network, the BMT
CTN has proven to be a successful infrastructure for plan-
ning, implementing, and completing such trials, providing
deﬁnitive answers to questions that have led to improve-
ments in the understanding and practice of HCT. It has opened
37 trials addressing important issues in the treatment of pa-
tients with life-threatening malignant and nonmalignant
blood disorders. These trials, about one-half phase 2 and one-
half phase 3, with a median enrollment of 180 (range, 17 to
1700), address issues of donor availability, engraftment, graft-
versus-host disease (GVHD), post-transplantation infection,
disease control, organ toxicity, cost-effectiveness, and quality
of life. The goal is to make HCT a therapy that is more uni-
versally available (by expanding donor sources and allowing
use in older, sicker patients), safer (by reducing regimen-
related toxicity, life-threatening infection, and GVHD), and
effective (by various strategies to prevent relapse). Illustra-
tive studies and ﬁndings are listed in Table 1.
Numerous advances substantially changed the land-
scape of HCT over the decade and one-half since
establishment of the BMT CTN, and BMT CTN trials played a
key role in developing many of them, building on preclini-
cal and early clinical work being done in its member centers
and elsewhere. In the early days of the BMT CTN, complica-
tions of HCT, especially GVHD, limited the effectiveness and
availability of the procedure. Nearly one-half of the pa-
tients in need of HCT, including most patients in ethnic
minority groups, particularly African-Americans, were denied
the procedure because they did not have available matched
donors. Older and less ﬁt patients were deemed to not be can-
didates for HCT because of toxicity concerns. BMT CTN–led
trials evaluating use of unrelated umbilical cord blood and
related haploidentical donor transplantation after reduced-
intensity conditioning conﬁrmed the safety and effectiveness
of these alternative allograft sources in themulticenter setting,
with results close to those seen with HLA-matched donors
[16]. The BMT CTN, working collaboratively with the NCI-
supported cooperative group The Alliance for Clinical Trials
in Oncology (previously CALGB), also validated single-
center data that reduced-intensity conditioning allows
allogeneic HCT to be used effectively in patients with acute
myeloid leukemia (AML) older than 60 years, with either an
HLA-identical sibling or unrelated donor [19]. These studies
helped expand applicability of HCT to many more patients
with both malignant and nonmalignant blood disorders, in-
cluding patients in their 70s. Additionally, >30% of participants
in the ongoing BMT CTN phase 3 trial randomized to either
unrelated umbilical cord blood or related haploidentical al-
lografts are from ethnic minority groups, and patients into
their 70s are eligible.
The availability and effectiveness of HCT make it an im-
portant platform for incorporating novel therapies. HCT not
only provides a state of minimal residual disease but, in the
case of allografting, also a new nontolerant immune system.
The BMT CTN is at the forefront of trials combining HCT with
novel therapeutics. Its collaboration with the Alliance to com-
plete a randomized trial of lenalidomide maintenance after
HCT for multiple myeloma, a trial almost closed for poor
accrual before BMT CTN’s participation, proved to be prac-
tice changing [18]. A trial adding a dendritic cell vaccine to
post-transplantation maintenance in this setting is about to
be launched. These and other studies represent a next gen-
eration of BMT CTN trials studying post-HCT strategies to
improve response and reduce relapse (see below).
NETWORK STRUCTURE
The initial structure funded 16 clinical core centers, ge-
ographically distributed throughout the United States; several
of these core centers were consortia of 2 or more institu-
tions. The Data and Coordinating Center (DCC) is a consortium
of 3 organizations, each with extensive experience in HCT:
the CIBMTR, the Emmes Corporation, and the NationalMarrow
Donor Program (NMDP)/Be The Match. The CIBMTR is a col-
laborative research program of the Medical College of
Wisconsin, Milwaukee, and NMDP/Be The Match, Minneap-
olis, with oﬃces on both campuses. Non-CIBMTR departments
of NMDP/Be The Match handle contracts and ﬁnances for the
network. The Emmes Corporation is a contract research or-
ganization in Rockville, Maryland that managed 2 previous
national HCT trials funded by NHLBI: the T Cell Depletion Trial
in Unrelated DonorMarrow Transplantation [24] and the Cord
Blood Transplantation Trial [25]. The DCC grant was awarded
to the Medical College of Wisconsin with subcontracts to
NMDP/Be The Match and Emmes. Today the BMT CTN is in
its third grant cycle. Although subsequent cycles brought some
changes, including increasing the number of core centers to
20, the basic structure is the same (Figure 1).
The BMT CTN steering committee sets the scientiﬁc agenda
and oversees selection, design, execution, and analysis of all
BMT CTN studies. The BMT CTN steering committee in-
cludes the principal investigator of each core center or
consortium and the DCC, the NHLBI project oﬃcer, the NCI
project oﬃcer, a representative of each of the NCI-funded co-
operative groups, and representatives of aﬃliate centers that
meet standards for exemplary participation in BMT CTN trials.
Protocols are developed by protocol teams, each com-
posed of 2 ormore protocol cochairs, 5 to 7 other investigators,
an NHLBI and an NCI representative, a DCC protocol oﬃcer,
who is a medical doctor with clinical trials training and ex-
perience, a DCC protocol coordinator, a DCC statistician, and
an NHLBI statistician. Protocol development begins after a
concept (presented at a very early stage of development) is
accepted by the steering committee and is facilitated by
weekly conference calls and, recently, by 1 or more in-
person meetings of the protocol team.
Independent review committees appointed by NHLBI
provide additional oversight for BMT CTN trials. The proto-
col review committee evaluates each study for scientiﬁc merit
and 2 data and safety monitoring boards are each responsi-
ble for about one-half of the network portfolio. Each of these
includes a chair and members with expertise in biostatis-
tics, clinical trials, bioethics, HCT, and speciﬁc disease areas
of network studies.
ACCOMPLISHMENTS
Since launching its ﬁrst trial in November 2003, the BMT
CTN has an outstanding record of accomplishments. A few
(current through October 2015) are listed below:
• The network opened 37 clinical trials addressing impor-
tant issues in the treatmentof patientswith life-threatening
blood disorders; to date, the network has enrolled >8300
participants from >120 centers on these trials.
BMT CTN was the lead group for 30 trials; 5 were devel-
oped in collaboration with other NIH-funded groups, and
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Table 1
Selected BMT CTN Studies with Signiﬁcant Findings
Evaluating Conditioning Regimens
0301 Phase I/II trial of ﬂudarabine-based conditioning for allogeneic marrow transplantation from human leukocyte antigen (HLA)-compatible unrelated donors in
severe aplastic anemia: Optimizing transplantation regimens for rare diseases is diﬃcult and requires a multicenter effort. This study determined that ﬂudarabine is not
suﬃciently immune suppressive to replace cyclophosphamide in conditioning regimens for unrelated donor transplantation for aplastic anemia. Additionally, it found excess
toxicity with a commonly used dose of cyclophosphamide when combined with ﬂudarabine. This unexpected ﬁnding is anticipated to change practice in many centers [3,4].
0401 Phase III trial comparing Rituxan/BEAM versus Bexxar/BEAM prior to autologous HCT for persistent or relapsed chemotherapy-sensitive diffuse large B cell
non-Hodgkin lymphoma (DLBCL): Determined that addition of radioimmunotherapy to the standard conditioning regimen of BEAM provides no clinical beneﬁt for patients
undergoing autologous HCT for DLBCL. Although several small phase 2 studies suggested that dose intensiﬁcation might decrease relapse, the primary cause of treatment
failure after autologous HCT for DLBCL, this study failed to show an impact on relapse but did show increased toxicity. Future trials will focus on maintenance strategies and/or
immune therapies after HCT to improve disease control, marking a signiﬁcant change in direction for the ﬁeld [5].
0601 Phase II trial of unrelated donor HCT for children with severe sickle cell disease using a reduced-intensity conditioning regimen: Determined that a reduced-intensity
conditioning regimen of alemtuzumab, ﬂudarabine, and melphalan, although effective for engraftment of bone marrow, was associated with unacceptably high levels of graft
failure after cord blood transplantation in children with sickle cell anemia. This disappointing ﬁnding using cord blood indicates the need for novel strategies for the large
number of sickle cell disease patients who cannot ﬁnd an HLA-matched adult donor [6].
GVHD Prevention and Treatment
0303: A single-arm, multicenter Phase II trial of transplants of HLA-matched, CD34+ enriched, T cell depleted peripheral blood stem cells isolated by the CliniMACS system
in the treatment of patients with acute myeloid leukemia (AML) in ﬁrst or second complete remission: Conﬁrmed, in a multicenter setting, the feasibility and consistency
of T cell depletion by CD34 selection, with results in AML that warranted development of a phase 3 trial versus non-T cell–depleted transplantation. These data were used by
the Food and Drug Administration in its determination to approve, for the ﬁrst time, a CD-34–selection column for clinical use in the United States. A phase 3 trial comparing
outcomes of CD34-selected transplantations using this approach with standard bone marrow transplants followed by calcineurin-inhibitor–based GVHD prophylaxis (BMT CTN
1301 PROGRESS II) has recently opened in the BMT CTN [7].
0302: Initial systemic treatment of acute GVHD: a Phase II randomized trial evaluating etanercept, mycophenolate mofetil, denileukin diftitox, and pentostatin: Identiﬁed
the most promising agent to move into a phase 3 trial (see 0802 below). Data from this trial were also used to determine that GVHD biomarker panels can be used for early
identiﬁcation of patients at high or low risk for treatment nonresponsiveness or death and that biomarker panels may provide opportunities for early intervention and
improved survival after HCT. The wider use of biomarkers to identify patients at high risk of GVHD will allow us to tailor our therapies to better control this complication in
these patients and to reduce toxicity in patients who are unlikely to beneﬁt from intensive immune suppression. The BMT CTN is now incorporating biomarker-deﬁned risk
stratiﬁcation into the design of its GVHD treatment trials [8-10].
0802: A Phase III randomized, double blind trial evaluating corticosteroids with mycophenolate mofetil versus corticosteroids with placebo as initial systemic treatment
of acute GVHD: Found no beneﬁt in GVHD-free survival when mycophenolate mofetil was added to corticosteroids for initial therapy of acute GVHD requiring system
treatment. Although these results were discouraging, the BMT CTN has used these data to focus on a newer therapeutic agent, sirolimus, in the upcoming BMT CTN 1501 study
using a biomarker risk stratiﬁcation developed in BMT CTN 0302 and 0802 to identify patients with standard risk who might be able to avoid corticosteroid therapy. Other
agents are being considered for testing in patients with high-risk acute GVHD. The network’s ability to conduct GVHD trials in a timely manner allows for deﬁnitive phase 3
results to be quickly disseminated and promising agents to be eﬃciently tested.
0402: A Phase III randomized, multicenter trial comparing sirolimus/tacrolimus with tacrolimus/methotrexate as GVHD prophylaxis after HLA-matched, related
peripheral blood stem cell transplantation: Identiﬁed a high risk of toxicity when sirolimus is substituted for standard methotrexate for GVHD prophylaxis when the
conditioning regimen includes busulfan, and no advantage in acute GVHD-free survival. Although this study showed a modest improvement in grade III-IV acute GVHD, the
ﬁndings do not support substituting sirolimus for methotrexate since it may increase toxicity in patients who receive busulfan for conditioning, it was associated with higher
risks of chronic GVHD, and it did not improve survival. Novel approaches to preventing GVHD are needed and are being explored in the accruing BMT CTN 1203 PROGRESS I and
1301 PROGRESS II studies [11,12].
Graft Sources
0501: Multicenter, open-label, randomized trial comparing single versus double umbilical cord blood transplantation in pediatric patients with leukemia and
myelodysplasia: Demonstrated no survival beneﬁt and more acute GVHD for children receiving infusion of 2 umbilical cord blood units versus 1 umbilical cord blood unit after
transplantation for hematologic malignancies. This collaborative study with the Children’s Oncology Group indicates, unexpectedly, that increasing cell dose beyond the
accepted minimum by adding another cord blood unit does not improve survival after cord blood transplantation in children and increases the risk of acute GVHD. This has
important implications for future strategies to improve hematopoietic recovery and decrease transplantation-related mortality after cord blood HCT [13].
0201: A Phase III randomized, multicenter trial comparing G-CSF mobilized peripheral blood stem cell with marrow transplantation from HLA compatible unrelated
donors: Found no difference in survival for recipients of unrelated donor peripheral blood versus bone marrow grafts, but an increased risk of chronic GVHD requiring
prolonged immune suppression with peripheral blood grafts. Although peripheral blood has largely replaced bone marrow as a graft source for unrelated donor transplantation,
this study suggests that this may not be appropriate in the myeloablative conditioning setting, which has important implications for clinical practice. This is the largest
prospective study of unrelated donor transplantation ever performed. It would not have been possible without the infrastructure provided by the BMT CTN. An ancillary study
shows that patients in this trial were representative of the larger population of patients receiving HCT during the time period [14,15].
0603/0604: Multicenter, Phase II trials of non-myeloablative conditioning and transplantation of partially HLA-mismatched bone marrow/umbilical cord blood from
unrelated donors in patients with hematologic malignancies: Conﬁrmed single-center results in a multicenter setting using reduced-intensity conditioning and
haploidentical bone marrow transplantation or double cord blood transplantation in adults with hematologic malignancies, with data supporting a subsequent phase III trial.
Acceptable outcomes of double cord and haploidentical bone marrow transplantation suggest that many more adults should be offered HCT, even when an HLA-matched adult
donor is not available. These approaches are now being compared in a randomized phase III trial (BMT CTN 1101) [16,17].
Disease Treatment
0704 (CALGB 100104): A Phase III, randomized, double-blind study of maintenance therapy with CC-5013 or placebo following autologous stem cell transplantation for
multiple myeloma: Determined lenalidomide maintenance therapy dramatically improves progression-free survival and overall survival after autologous HCT for multiple
myeloma. The BMT CTN was an important contributor to this study, which was led by Cancer and Leukemia Group B and used its Network and the CIBMTR database to devise
an accrual plan that allowed the trial to successfully meet its enrollment target after initial accrual diﬃculties. The data have led to a major change in clinical practice, with
most myeloma patients now receiving lenalidomide maintenance after transplantation [18].
0502 (CALGB 100103): Phase II study of allogeneic HCT for older patients with AML in ﬁrst morphologic complete remission using a non-myeloablative preparative
regimen: Demonstrated the feasibility and effectiveness of allogeneic HCT using reduced intensity conditioning in this ﬁrst prospective US cooperative group trial conducted in
a homogeneously treated group of older AML patients in ﬁrst remission. The study demonstrates that, with reduced-intensity conditioning, patients older than 60 can beneﬁt
from the graft-versus-leukemia effects of allogeneic HCT with outcomes similar to younger patients. These data should increase the use of HCT in older AML patients and
provides justiﬁcation for extending the upper age range in allograft trials [19].
0701: Phase II trial of non-myeloablative allogeneic HCT for patients with relapsed follicular non-Hodgkin lymphoma beyond ﬁrst complete response: Demonstrated that
allogeneic HCT using a rituximab-containing reduced-intensity conditioning regimen confers high complete response rates, a low incidence of relapse/progression, and
prolonged survival with acceptable toxicity in heavily pretreated follicular lymphoma patients [20]. This study provides justiﬁcation for future trials comparing
nontransplantation with transplantation salvage strategies in this disease, which has the potential to change practice.
Supportive Care
0101: A randomized double-blind trial of ﬂuconazole versus voriconazole for the prevention of invasive fungal infections in allogeneic blood and marrow transplant
recipients: Demonstrated that ﬂuconazole, a low-cost antifungal agent, has similar eﬃcacy and is generally more cost-effective than the newer and more expensive drug,
voriconazole, in preventing serious fungal infections in the ﬁrst 6 months after HCT but that voriconazole may be cost-effective for those undergoing allogeneic HCT for AML.
This phase 3 comparison of ﬂuconazole and voriconazole indicates that newer is not always better and that, for most patients, standard ﬂuconazole is effective fungal
prophylaxis. However, an ancillary study suggested there is a subset of patients for whom primary antifungal prophylaxis with voriconazole may be more appropriate, allowing
more informed treatment planning by transplantation centers [21,22]. Both of these ﬁndings inform general HCT practice.
Quality of Life
0902: A Phase III randomized, multicenter trial testing whether exercise or stress management improves functional status and symptoms of autologous and allogeneic
recipients: Demonstrated no improvement in physical or mental quality of life with exercise training, stress management training, or combined stress management and
exercise training compared to usual care. This trial tested modest, easily applied interventions in the early transplantation period. While lack of an effect was disappointing, the
trial enrolled more than 700 patients in 19 months, demonstrating that the BMT CTN has an effective infrastructure to conduct studies addressing quality of life issues [23].
BEAM indicates BCNU, etoposide, cytarabine, melphalan; DLBCL, diffuse large B cell lymphoma; G-CSF, granulocyte colony–stimulating factor.
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2 were developed in collaboration with NIH-funded
investigators.
Twenty-four trials (19 led by BMT CTN) completed en-
rollment and patient follow-up, 2 trials completed
enrollment but follow-up is ongoing, and 11 are still en-
rolling patients.
• BMT CTN trials have a high rate of accrual success and
impact.
Only 2 BMT CTN–led trials were closed for poor accrual;
of note, both led to peer-reviewed publications [26,27].
Sixteen of the other 19 BMT CTN–led trials with com-
pleted accrual ﬁnished within 6 months of projections.
BMT CTN 0201 was the largest randomized trial of unre-
lated donor transplantation and showed that using bone
marrow rather than peripheral blood grafts reduces chronic
GVHD and improves long-term quality of life [14].
BMT CTN 0303, a study of CD34-selected allografts for
AML, led to the ﬁrst Food and Drug Administration ap-
proval of a cell-selection device for clinical use in the
United States [7].
BMT CTN 0603 was the ﬁrst multicenter trial to show the
safety and effectiveness of related haploidentical bone
marrow transplantation, resulting in dramatic increases
in use of this HCT approach [16].
BMT CTN 0502/CALGB 100701 demonstrated the eﬃca-
cy of related and unrelated donor transplantation with
reduced-intensity conditioning in older patients with AML
[19].
BMT CTN 0704/CALGB 100104 proved the activity of
lenalidomide as post-transplantationmaintenance therapy
for multiple myeloma, demonstrating a beneﬁt in both
progression-free and overall survival [18]. An ongoing trial,
BMT CTN 0702, builds on this trial to address the role of
post-transplantation consolidation and second transplan-
tation in an era when almost all patients receive post-
transplantation maintenance.
• The network developed a research repository that cur-
rently houses >350,000 donor and recipient specimens;
these specimens and linked data are made available to
qualiﬁed investigators (www.bmtctn.net—research ma-
terials). To date, there are 8 ancillary publications resulting
from analyses of these samples and data [8,9,28-33]. One
resulted in a novel biomarker for outcome of acute GVHD
and is currently being used by the network to stratify
patients for intervention studies [8,9]. Ancillary studies
are encouraged by network RFAs that solicit concise
concepts that are quickly reviewed and—where
appropriate—awarded, with awardees monitored closely
for productivity.
• The network incorporated standard assessment of patient-
reported outcomes into its trials and has conducted 1 trial
speciﬁcally assessing post-transplantation quality of life
[23].
• The network published 57 peer-reviewedmanuscripts, in-
cluding 16 primary results papers [3,5,7,10,11,13,14,16,18,
19,21,23,26,27,34,35] and 41 others, addressing diverse
issues of disease biology, deﬁning and staging post-
transplantation complications, state of the science, patient-
reported outcomes, cost-effectiveness, and trial design
[2,4,6,8,9,12,15,17,22,28-33,36-61].
Seventeen of 19 BMT CTN–led studies reaching primary
endpoint are published or submitted for publication; 2
studies completed in the last year will be submitted soon.
The median time from reaching primary endpoint to
having an analysis available for review by the protocol team
was 27 days.
Eighty-one percent of completed studies had a primary
manuscript submitted within 1 year of the ﬁnal data anal-
ysis, and the median time to submission was 7.6 months.
In a study done by the NHLBI to evaluate the impact of
network publications compared with other publications
addressing similar issues, 63% of the network papers pub-
lished before 2013 (the most recent date for which this
analysis was performed) had an impact score in the top
5th percentile and 86% had an impact score in the top 20th
percentile.
Figure 1. BMT CTN organizational structure.
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• The network leveraged NIH support to develop public-
private collaborations that have provided an additional
$332,000,000 of in-kind and $36,000,000 of direct support
for BMT CTN trials.
KEYS TO SUCCESS
In many ways, the structure and operations of the BMT
CTN are similar to those of many other multicenter trials
groups. Yet, its accrual and publication productivity are su-
perior to those observed in several other networks during the
same time period [62]. The Institute of Medicine noted that
only 60% of the trials launched by the NCI-funded coopera-
tive groups before 2010 achieved minimum accrual goals. A
series of reports by Dilts et al. described extremely long times
from concept to activation for phase 3 cancer trials, ranging
from 1.25 to almost 7 years, because of complex bureaucrat-
ic review processes involving multiple oversight bodies
[63-66]. These critiques led to a major reorganization of the
cancer clinical trials infrastructure, which aims to improve
eﬃciency and productivity. A recent publication reported that
results of less than two-thirds of NHLBI-funded cardiovas-
cular trials were published within 30 months of completion
[67]. Another recent study of US academic medical centers
found only 36% of completed trials with results published
within 24 months of completion [68]. In considering the
history of the BMT CTN, there are unique features that helped
the network achieve its goal: completing important multi-
center trials addressing critical issues in HCT.
Streamlined Infrastructure
Although largely similar to other networks, there are a few
structural differences. The BMT CTN resisted the tempta-
tion to have standing disease- ormodality-focused committees
with primary responsibility for setting the scientiﬁc agendas
in their areas. Instead, this responsibility resides with the
larger steering committee, guided by community input gar-
nered, in large part, from periodic State of the Science
Symposia (see below). Committees are formed ad hoc to plan
the State of the Science Symposia to act on the Symposia’s
conclusions, and to address other issues as necessary (eg,
review the portfolio of studies in GVHD, consider condition-
ing regimen dose modiﬁcations for obese patients). The
steering committee also considers input from other rele-
vant sources, such as the NHLBI’s recent strategic visioning
initiative (http://www.nhlbi.nih.gov/about/documents/
strategic-visioning). The network’s 5 standing technical com-
mittees (biomarkers, special populations, toxicity and
supportive care, pharmacy, and clinical research associates
committee) have speciﬁc roles in protocol development and
review but not in setting the scientiﬁc agenda. The lack of
standing committees avoids expectations to have a proto-
col in every topic area and brings a broader perspective to
assigning priority. It also decreases the administrative burden
of committee support for the DCC. It should be acknowl-
edged that this is possible because HCT is already a relatively
specialized area and the steering committee itself pos-
sesses a breadth of knowledge and expertise that allows
intelligent discussion of most issues and of most diseases for
which HCT is a potential treatment. The committee is quick
to invite additional expertise for those topics that require it.
Governance of the steering committee is also unique. The
chair position is rotated, with members electing individu-
als to a nonrenewable 2-year term, preceded by 2 years as
vice-chair and 1 year as chair elect and succeeded by a 1-year
term as past chair. Consequently, during its almost 15-year
existence, the network has had 8 chairs from 8 different in-
stitutions (Table 2). Each made unique contributions to the
network and each gained a deeper understanding of the issues
faced in implementing the network’s scientiﬁc agenda, aug-
menting their capacity for continued contributions on the
steering committee. This rotating approach increases the sense
of ownership of the membership, since leadership posi-
tions are not concentrated in just a few people from a
restricted number of centers.
Inclusivity and Collaboration
BMT CTN core centers include large and medium-sized,
adult and pediatric centers that are widely geographically dis-
tributed (Table 3). Seven of the 20 core centers are consortia
that comprise, in total, 22 centers. The Pediatric Blood and
Marrow Transplant Consortium is also a BMT CTN core center
and comprises more than 70 US pediatric HCT programs, 61
of which have enrolled patients on network protocols. Ad-
ditionally, the BMT CTN encourages and facilitates broad
participation of the HCT community through its aﬃliate center
system, whereby centers apply to participate in speciﬁc pro-
tocols through BMT CTN’s public website (www.bmtctn.net).
About 20% of the BMT CTN’s overall accrual comes from af-
ﬁliate centers. Additionally, investigators from aﬃliate centers
are invited to serve on state of science committees (see below)
and may propose new studies using the same process as the
members of core centers or consortia, also found on the public
website. The BMT CTN also encourages investigators from af-
ﬁliate centers to serve on network committees and protocol
teams. BMT CTN steering committee meetings are open to
investigators from aﬃliate centers and those that accrue at
least 12 patients annually onto at least 2 studies are given
voting membership on the committee. The network also
Table 2
BMT CTN Steering Committee Chairs
Chair Institution Term
John R. Wingard, MD University of Florida, Gainesville 2001-2003
Daniel J. Weisdorf, MD University of Minnesota, Minneapolis 2004-2005
James L. Ferrara, MD University of Michigan, Ann Arbor* 2006-2007
Joseph H. Antin, MD Dana Farber Cancer Institute, Boston, Massachusetts 2008-2009
Sergio A. Giralt, MD MD Anderson Cancer Center, Houston, Texas† 2010-2011
Ginna G. Laport, MD Stanford University, Palo Alto, California 2012-2013
Frederick R. Appelbaum, MD Fred Hutchinson Cancer Center, Seattle, Washington 2014-2015
Steven M. Devine, MD The Ohio State University, Columbus 2016-2017
Richard J. Jones, MD‡ The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 2018-2019
* Currently at Mount Sinai Medical Center, New York, New York.
† Currently at Memorial Sloan Kettering Cancer Center, New York, New York.
‡ Currently serving as vice-chair.
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encourages involvement of junior investigators, from both core
and aﬃliate centers, on protocol teams and other network
committees. Some of these early-mid career investigators re-
cruited to participate in the network subsequently become
part of the network leadership, including the current chair
of the steering committee.
The BMT CTN collaborates with other networks with over-
lappingmissions, including the NCI cancer cooperative groups
(the National Clinical Trials Network). Seven of the trials
opened by the BMT CTNwere led by an NCI cooperative group
or were separately funded by an NCI grant. One or more NCI
cooperative groups participated in 6 BMT CTN–led trials. Ad-
ditionally, the network has collaborated with the AIDS
Malignancy Consortium, the Canadian Blood and Marrow
Transplant Group, the National Institute of Allergy and In-
fectious Diseases, the National Institute on Minority Health
and Health Disparities, the NIH Oﬃce of Rare Diseases Re-
search, and the Sickle Cell Disease Clinical Research Network
for a variety of trials. The philosophy of the network is that
there are limited resources for multicenter trials; these are
usedmost eﬃciently when the community collaborates rather
than competes so that each trial accrues on schedule. For
example, the network delayed opening BMT CTN 0702 while
it collaborated with the Alliance to complete CALGB 100104/
BMT CTN 0704 (see above).
Inclusivity and collaboration also mark the processes for
setting the scientiﬁc agenda. A diverse group of voices con-
tribute to deliberations of the BMT CTN steering committee.
This group has worked together to build a scientiﬁc agenda
that is compelling and feasible and that considers propos-
als from individuals and groups outside the network. The
scientiﬁc agenda includes consideration of the need for a
network to address a pressing problem, gap areas within the
missions of NHLBI and NCI, patient availability and referral
patterns, and competing studies. BMT CTN largely sets its
longer-term scientiﬁc agenda at periodic State of the Science
Symposia, which also solicits input from the broader scien-
tiﬁc community [40,52,57]. The structure for these symposia
involves constituting disease- and issue-speciﬁc commit-
tees with members from diverse HCT and non-HCT
backgrounds. These committees deliberate for several months
prior to an open, in-person forum, to identify the most prom-
ising areas for HCT trials and to develop compelling study
proposals in those areas. Proposals are presented at the forum,
with reviews provided by external reviewers (including in-
ternational experts) and with opportunities for public
comment. A planning committee comprising committee
chairs, NIH representatives, and external reviewers then pri-
oritizes the trial concepts. Three State of the Science Symposia
were held in 2001, 2007 and, most recently, in 2014. Al-
though the proceedings of the initial symposium in 2001
(which preceded establishment of the network) were not pub-
lished, the BMT CTN completed 9 of its recommended studies.
Trial prioritizations from the 2007 symposium are well docu-
mented [40] as are the outcomes [52]: 9 of the 11 trials
recommended were undertaken with 4 completed and 5
ongoing. The 2014 State of the Science Symposium was the
largest to date, with 13 committees including 112 commit-
tee members, 20 external reviewers, and more than 300
attendees at the open forum. Ultimately, 12 concepts were
prioritized [57]. The BMT CTN is now developing many of
these studies, with several scheduled to open in 2016.
Access to the CIBMTR Database
A key asset of the BMT CTN is access to comprehensive
current clinical data about the population for whommost of
its trials are intended. The CIBMTR maintains, with sepa-
rate support of the NIH and the Health Resources and Services
Administration and aided by a 2005 federal requirement for
reporting HCT outcomes data, an observational database of
information on almost all of the HCTs performed in the United
States (www.cibmtr.org). This database provides invaluable
information that allows the BMT CTN to assess the feasibil-
ity of study proposals, to consider potential eﬃcacy of new
agents, to design protocols with appropriate inclusion crite-
ria and outcome estimates, and to recruit centers likely to
Table 3
BMT CTN Core Centers and Principal Investigators
Baylor College of Medicine/Methodist Hospital (consortium);
PI: Helen Heslop, MD, DSc (Hon)
1. Baylor College of Medicine/Methodist Hospital, Houston, Texas
2. Children’s National Medical Center, Washington, DC
Case Western Reserve University Ireland Cancer Center (consortium);
PI: Hillard Lazarus, MD
1. Case Medical Center, Cleveland, Ohio
2. Oregon Health Sciences (Adults), Portland
3. Cleveland Clinic, Ohio
4. West Virginia University, Morgantown
City of Hope National Medical Center, Duarte, California;
PI: Ryo Nakamura, MD
Dana Farber/Partners in Cancer Care (consortium);
PI: Joseph Antin, MD
1. Dana Farber Cancer Institute, Boston, Massachusetts
2. Brigham &Women’s Hospital, Boston, Massachusetts
3. Massachusetts General Hospital, Boston
4. Boston Children’s Hospital, Massachusetts
Duke University Medical Center, Durham, North Carolina;
PI: Joanne Kurtzberg, MD
Fred Hutchinson Cancer Research Center, Seattle, Washington;
PI: Frederick Appelbaum, MD
H. Lee Moﬃtt Cancer Center, Tampa, Florida; PI: Claudio Anasetti, MD
Johns Hopkins University Oncology Center, Baltimore, Maryland;
PI: Richard Jones, MD
Memorial Sloan-Kettering Cancer Center, New York, New York;
PI: Sergio Giralt, MD
Northside Hospital, Atlanta, Georgia; PI: Asad Bashey, MD, PhD
Ohio State University Comprehensive Cancer Center (consortium);
PI: Steven Devine, MD
1. The Ohio State University, Columbus
2. Roswell Park Cancer Institute, Buffalo, New York
3. University of North Carolina, Chapel Hill
4. University of California-San Francisco
5. Virginia Commonwealth University, Richmond
Pediatric Blood & Marrow Transplant Consortium, 70 centers in the
United States and Canada; PI: Michael Pulsipher, MD
Stanford Hospital and Clinics, Palo Alto, California;
PI: Robert Negrin, MD
University of Florida College of Medicine (Consortium);
PI: John Wingard, MD
1. University of Florida, Gainesville
2. Emory University, Atlanta, Georgia
University of Michigan Medical Center Consortium;
PI: Gregory A. Yanik, MD
1. University of Michigan, Ann Arbor
2. Mayo Clinic, Rochester, Minnesota
3. Mt. Sinai Hospital, New York, New York
University of Minnesota, Minneapolis; PI: Daniel Weisdorf, MD
University of Nebraska Medical Center (consortium);
PI: Julie Vose, MD
1. University of Nebraska, Omaha
2. University of Kansas, Kansas City
University of Pennsylvania Hospital, Philadelphia;
PI: Edward Stadtmauer
University of Texas MD Anderson Cancer Center, Houston;
PI: Amin Alousi, MD
Washington University, St. Louis, Missouri;
PI: Peter Westervelt, MD, PhD
PI indicates principal investigator.
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accrue. Once trials are opened, the database is used to prompt-
ly and effectively address accrual barriers by assessing
characteristics of persons who do and those who do not enroll
on the trial. Data collected by the CIBMTR also complement
data collected through the BMT CTN’s clinical trials system,
thereby easing the data-reporting burden for centers, though
requiring additional coordination and technical interfaces
between the 2 data systems. Because the CIBMTR follows
transplantation recipients long term, a separate long-term
follow-up system is not necessary for patients on BMT CTN
trials. The value of having CIBMTR data to design, conduct,
and monitor studies that can successfully accrue cannot be
underestimated and is perhaps the most unique and impor-
tant among the features contributing to the network’s success.
Innovative uses of the CIBMTR database to complement trials
are being further explored, including using CIBMTR registry
data to dramatically minimize data collection for quality-of-
life trials (BMT CTN 0902) and prospective enrollment of
controls for comparison to data in phase 2 trials (BMT CTN
1203).
Accountability
The BMT CTN has well-deﬁned metrics for all aspects of
protocol development, implementation, and completion. These
are used to focus individual protocol teams and the network
on ensuring the success of each study, to quickly identify when
obstacles to success arise, and to implement effective
remedies.
Protocol development and completion
Concepts for protocols are accepted for review at a very
early stage of development, generally before a well-deﬁned
statistical or treatment plan is developed. (This contrasts to
the current requirement for concepts submitted to the NCI
disease-speciﬁc steering committees for implementation in
the National Clinical Trials Network, which require a higher
degree of development.) Consequently, careful oversight of
the development process is necessary to avoid long delays
to implementation (Figure 2). Once the steering committee
approves a concept to be developed into a protocol, a pro-
tocol team is assembled (see above); the benchmark for having
protocol documents ready for submission to the protocol
review committee is 6 months. The median time has de-
creased from 8.5 to 4.6 months over the life of the network
and most protocols now meet the benchmark, though a few
have been delayed by need for Food and Drug Administra-
tion approval or contract negotiations with pharmaceutical
or biotechnology companies.
The 2-step review process by the protocol review com-
mittee and the data and safety monitoring board is generally
eﬃcient, taking a median of 2.6 months. Review by the BMT
CTN’s technical committees occurs in parallel. The bench-
mark for activation once a protocol is released to centers is
5 months; the current median is 4.7 months.
Each protocol is accompanied by an accrual plan that in-
cludes projected quarterly accrual numbers and a detailed
blueprint for ensuring that projections are met. This plan can
include recruitment of speciﬁc aﬃliate centers, develop-
ment of patient and physician educational materials, outreach
to patient advocacy groups, and targeted presentations at
transplantation and referral centers and key conferences.
Actual versus projected accrual rates are available on the BMT
CTN’s private website and updated nightly. They are re-
viewed monthly by the protocol teams with early institution
of actions to address less-than-expected accrual. As noted
above, these are assisted by analyses of the CIBMTR database.
A plan for reviewing endpoint data is also part of proto-
col development. Usually this begins early in the life of the
trial to avoid lengthy delays for data review after the last
patient reaches primary endpoint. In general, a data set is
available for review by the protocol team within 1 month of
the latter event (median time, 27 days). The network bench-
mark for submitting amanuscript after receiving the ﬁnal data
set is 9 months; ﬁrst authorship can be reassigned from in-
vestigators that fail to meet this benchmark. Themedian time
is 7.6 months (range, 1.8 to 15.7). As noted above, 81% were
submitted less than 1 year after ﬁnal data analysis. Protocol
teams are also encouraged to plan ancillary papers early in
the protocol development process and to consider addition-
al ideas for secondary analyses as data become available.
Figure 2. Schema for protocol development and implementation. *Work on these documents/tasks begins during the protocol development phase and is gen-
erally close to completed by the time the ﬁrst institutional review board approvals are available. PRC = protocol review committee; DSMB = data safety and
monitoring board; IRB = institutional review board.
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Current and historical times for steps of the protocol devel-
opment and completion process are shown in Figure 3.
Development of robust data collection processes and eﬃcient
safety monitoring procedures
The ﬁrst tasks of the network were aimed at developing
tools for the eﬃcient collection of data from inherently dif-
ﬁcult studies. Committees made up of experts in HCT
outcomes designed a core set of case report forms for col-
lection of acute and chronic GVHD, post-transplantation
toxicities, engraftment, relapse, infection, and immune re-
constitution. This core set of case report forms is still in use
today, constituting a consistent and streamlined data collec-
tion process. Reporting adverse events in the HCT setting has
the potential to overwhelm the pharmacovigilance system,
but the network developed an eﬃcient model where only un-
expected grades 3 to 5 adverse events are reported in an
expedited manner and all expected events are reported on
calendar-driven case report forms. This lean adverse event
reporting process allows the network to separate the back-
ground noise from the plethora of expected events after HCT
while not compromising safety of study participants. The use
of independent medical monitors (typically transplantation
physicians or disease experts) allows unbiased review of un-
expected (or more frequent than expected) events and was
instrumental in early detection of events that led to closing
the umbilical cord blood cohort of an unrelated donor trans-
plantation trial for sickle cell disease and exclusion of
busulfan-conditioning regimens from a trial evaluating
sirolimus for GVHD prophylaxis after treatment of only 8 and
10 subjects, respectively [6,11].
Center performance
Successfully completing trials requires not only an eﬃ-
cient infrastructure but, more importantly, also a cadre of
high-performing centers committed to rapid activation and
eﬃcient accrual to trials that address important issues. Per-
formance of BMT CTN centers is formally assessed annually
in a report that evaluates scientiﬁc contributions, activa-
tion times, data quality and timeliness, protocol and laboratory
compliance, and accrual. Accrual rates are judged not only
by the absolute number enrolled on a study, with a minimum
number required from each center, but on how closely centers
meet their individual projections. The latter has led to more
careful consideration of accrual potentials by centers, which
leads to more realistic accrual projections by the DCC and
more rational decisions for protocol implementation by the
network. Center performance reports are shared openly at
the annual February steering committee meeting; no names
are changed to protect the innocent (or guilty). Centers failing
to meet metrics in any area must submit a corrective action
plan. Consistent failure to meet metrics can result in expul-
sion from the network. In addition to ensuring timely accrual,
the network has, through this process, improved its perfor-
mance on data quality and protocol and laboratory
compliance, with all of the 20 core centers meeting stan-
dards in these areas in the 2015 assessment. Similar
assessments are done for aﬃliate centers; past perfor-
mance affects the decision to allow participation in future
protocols.
Adequate Financial Support for Patient Enrollment and
Good Financial Stewardship
Enrolling and monitoring patients on clinical trials re-
quires substantial investment of time and resources. This is
especially true for HCT trials, which require extensive data
collection for the many adverse events expected in the early
post-transplantation time period. Most BMT CTN trials also
require multiple laboratory assessments both to monitor tox-
icity and to better understand themolecular and immunologic
determinants of outcomes. A formal assessment of the costs
of enrolling patients and of meeting protocol requirements
is done for each trial and per-patient reimbursement rates
are set by that assessment. Two studies of the actual time
spent by center staff on trial activities have been done during
the life of the network to reﬁne these estimates. The goal is
to have participation in BMT CTN trials be cost neutral, re-
moving negative (or positive) ﬁnancial incentives for patient
enrollment so that decisions to activate are made on scien-
tiﬁc grounds and compliance with protocol requirements is
facilitated. This is important in an era when health care in-
stitutions face increasing ﬁnancial constraints and pursuing
activities that losemoney becomesmore andmore untenable.
Together with a commitment to provide adequate reim-
bursement for trial-related costs, the network has a
commitment to provide careful oversight of limited NIH funds.
The total amount of dollars available for trials for each funding
period is known at the outset and the DCC has developed a
budgetingmodel that allows the costs of each study to be fore-
cast. Trial costs are reviewed quarterly, since changes in speed
of accrual and protocol modiﬁcations can alter projected costs.
The amount of money committed to existing or developing
protocols and the amount available for new protocols are re-
viewed at each in-person steering committee meeting. This
transparency leads to accountability. The entire steering com-
mittee understands the network’s ﬁnancial limitations and
takes responsibility for planning studies within a well-
deﬁned budget and within foci related to the distinct mission
of each sponsor. This understanding also provides strong in-
centive for pursuing public-private partnerships that extend
the power of that well-deﬁned budget to address issues that
would be otherwise impossible to support, given the total NIH
allocation. Such partnerships have increased the network’s
funding by >$360,000,000.
LESSONS LEARNED AND AREAS FOR IMPROVEMENT
Although we are proud of our accomplishments, it should
be noted that this network evolved over time and many of
the processes described above grew out of painful experi-
ence. It took 2 years for the network to launch its ﬁrst trial
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Figure 3. Timelines for steps in the protocol development and activation
process. (A) Time from protocol team formation to submission of protocol
to protocol review committee (PRC). (B) Time from submission to the PRC
to approval by the data safety and monitoring board (DSMB). (C) Time from
DSMB approval to activation. (D) Time from protocol team formation to ac-
tivation. (E) Time from reaching primary endpoint to manuscript submission.
All times are in months.
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in 2003! A few lessons from that and subsequent experi-
ences include the following: do as many steps as possible in
the protocol development process in parallel rather than
sequentially; resistance to accrual can be triggered by seem-
ingly trivial protocol requirements (remember, one person’s
“trivial” is another’s “critical”), so have supportive care prac-
tices not critical to the primary question implemented “per
institutional protocol” as much as possible; try to under-
stand the work ﬂow implications of pre- and post-
transplantation evaluations, including the need for visits that
might not otherwise occur; only perform the tests and collect
data that are essential to the goals of the trial—“nice to have”
is not a good rationale for a test or a data point; most HCT
trials will need many centers to accrue successfully so this
should be planned for from the beginning; never underes-
timate how long it will take to execute contracts with
contributors and start early; stay aware of potentially com-
peting trials, which means communicating with the
community often and effectively, and ﬁnd ways to collabo-
rate rather than compete whenever possible; and encourage
planning for ancillary studies and secondary analyses early,
rather than waiting until the trial is complete.
Still problematic for the network is eﬃcient activation of
trials at the individual-center level, where protocols are subject
to institution-speciﬁc processes and timelines for review and
approval. Although the network implemented some ap-
proaches to speed this process, such as early identiﬁcation
of a protocol champion at each center, frequent communi-
cation, and closemonitoring of each center’s progress, success
has been variable. The network is now piloting use of a single
institutional review board of record for some trials to try to
speed this. Even the areas in which we think we have effec-
tive processes require continuous monitoring and diligence
to avoid falling back into habits that delay development, ac-
tivation, and accrual.
THE FUTURE
HCT is a complex therapy and conducting effective mul-
ticenter trials must address complex issues. The network has
proven its ability to do this. It is now using this expertise to
study alternative donor approaches able to extend HCT to
populations with nonmalignant diseases and restricted donor
sources, eg, patients with hemoglobinopathies and with
marrow failure, as well as to patients with blood cancers. Two
trials in sickle cell disease, 1 evaluating the effectiveness of
HLA-matched related or unrelated donor transplantation as
compared to standard of care in young adults with severe
disease and the other the feasibility of HCT using HLA-
mismatched related donors, are planned for 2016. Another
trial will evaluate use of umbilical cord blood grafts and use
of HLA-mismatched bone marrow grafts for patients with
aplastic anemia. Trials in these rare blood disorders would
not be feasible without the network’s infrastructure and ex-
pertise. As novel approaches to cellular therapy of both
malignant and nonmalignant disease are developed, many
of which focus on the same diseases as HCT, the network is
well positioned to evaluate these approaches in the multi-
center setting. It is already beginning to do so. In 2016, the
network will launch a study to evaluate the eﬃcacy of a
dendritic cell vaccine in improving response after autotrans-
plantation formultiplemyeloma. It is also planning trials using
chimeric-antigen receptor T cells and natural killer cells in
the pretransplantation and post-transplantation settings as
well as trials combining HCT with targeted anticancer thera-
pies, based on emerging data that the activity of many novel
therapies is augmented in the setting of a nontolerant immune
system as provided by an allograft. An example is the planned
BMT CTN 1506 study, which is the ﬁrst trial testing, in a pro-
spective randomized fashion, pilot data from several centers
on the activity of Fms-like tryosine kinase 3 (FLT3) inhibi-
tion as maintenance therapy after allogeneic HCT for FLT3
positive AML. Continued federal support and collaboration
with the scientiﬁc community will allow us to leverage our
infrastructure to facilitate translation of a growing under-
standing of molecular genetics and immunobiology into
advances in clinical care and outcomes.
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